142 results about "Human umbilical vein endothelial cell" patented technology

The invention provides a method for building a hollow vascularized heart based on the 3D biological printing technology and the hollow vascularized heart and relates to the technical field of tissue engineering and biology. The method includes: performing reverse modeling to build a heart three-dimensional grid model, importing the data of the heart three-dimensional grid model into a double-nozzle biological printing machine, and driving the nozzles of the printing machine to move according to a predesigned CAD digital model and selected forming parameters, wherein the nozzle 1 of the printing machine is loaded with sacrificial materials and used for printing a support framework, the nozzle 2 of the printing machine sprays biological ink to obtain building bodies, and the effective components of the biological ink comprise hydrogel, platelet-rich plasma, third-generation human umbilical vein endothelial cells and SD rat primary cardiomyocytes; crosslinking and cleaning the building bodies, and performing three-dimensional culture to form the hollow vascularized heart. The method has the advantages that the problem that a large-size hollow vascularized heart is hard in integrated printing, and the hollow vascularized heart built by the method is high in cell activity and has certain functions.

The invention relates to an HUVEC (human umbilical vein endothelial cell) separation, culture and subculture method belonging to the technical field of biology. The method comprises the following steps: (1) separation of HUVEC: taking a fresh umbilical cord, cleaning with a sterile PBS (phosphate buffer solution) containing penicillin-streptomycin, adding collagenase to perform water bath digestion at 37 DEG C, centrifuging the digestion solution, then adding an M199 culture medium, transferring into a gelatin-coated culture bottle, and culturing in a CO2 incubator at 37 DEG C; (2) culture of HUVEC: after the HUVEC is cultured at 37 DEG C for 24 hours, pouring out the culture medium, cleaning with the PBS, adding a fresh M199 culture medium, and afterwards, changing the culture medium once every two days, wherein the HUVEC can be subcultured generally after being cultured for 5-7 days; and (3) subculture of HUVEC: pouring out the culture medium, cleaning with the PBS, adding the digestion solution to digest the cell, adding a DMEM (dulbecco's modified eagle medium) containing serum to terminate the reaction once the cell is rounded, centrifuging the digested cell, and adding a fresh culture medium, wherein the HUVEC subcultured for 2-3 generations is used for experiments. The separated HUVEC is economical and practical, is simple and easy to use, and is beneficial to obtaining required in-vitro experimental model cells.

The invention provides an expansion system in vitro for hematopoietic stem/progenitor cells used for expanding human umbilical cord blood in vitro of soluble fusion protein Dll1-RGD (Hdll1-RGD) of notch ligand of a vascular endothelial cell target. The effective expansion system in vitro is formed by taking human umbilical vein endothelial cells as supporting cells of a cultivation system, jointly applying exogenous growth factors SCF, TOP, FL, IL-6, IL-3 and own developed hDLL1-RGD, and co-cultivating with the hematopoietic stem/progenitor cells. According to the expansion system, the hDll1-RGD target is combined to the surface of a human umbilical vein endothelial cell, activated stimulation aiming at a notch receptor is provided for the hematopoietic stem cells, and self-renewal and propagation of the hematopoietic stem cells are maintained, so that a satisfactory expansion effect and favorable implantation capacity are obtained.

The invention relates to hyla simplex skin injury repair promotion polypeptides and genes as well as application thereof, and belongs to the field of biomedicine. The hyla simplex skin injury repair promotion polypeptides comprise Hylareleasin 3 and Hylareleasin 4, which are gene codes of hyla simplex, a Chinese amphibious animal, wherein the molecular weights of the Hylareleasin 3 and 4 are 1764.106 Daltons and 1707.05 Daltons respectively; the isoelectric points are 9.61 and 9.60 respectively; the complete sequences of the hyla simplex skin injury repair promotion polypeptides Hylareleasin 3 and Hylareleasin 4 are NH2-GLLDPVTHILGGFLRR-COOH and NH2-GLLDPVTNILGGLLRR-COOH respectively; the genes coded by both the polypeptides consist of 365 nucleotides; and the mature coding part comprises the nucleotides 217-264. The multiplication of human umbilical vein endothelial cells (HUVEC) and the activity of the HUVEC for releasing epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) are promoted by the synthetic hyla simplex skin injury repair promotion polypeptides; and the hyla simplex skin injury repair promotion polypeptides can be applied to preparing preparations for promoting multiplication and tissue regeneration of vascular endothelial cells and epidermic cells and treating wounds, burns and ulcers of the body surface. The hyla simplex skin injury repair promotion polypeptides also have the advantages of simple sequences and convenience for synthesis.

The invention relates to a decapeptide inhibiting angiogenesis and use thereof, belonging to the technical field of biological medicine. The decapeptide inhibiting angiogenesis provided by the invention is deprived from human Homo sapien with an amino acid sequence of YNWNSFGLRF and the molecular weight of 1303.4, and is named as Kp-10. The invention further provides use of the decapeptide inhibiting angiogenesis for preparing medicines for inhibition of angiogenesis, in particular relevant use of Kp-10 for preparing medicines for inhibition of angiogenesis dependent diseases such as cancer, rheumatoid arthritis, psoriasis, diabetes syndrome, and hemangioma. A series of experimental results in VEGF (Vascular Endothelial Growth Factor) induction shows that Kp-10 has obvious inhibition function in the proliferation experiment of human umbilical vein endothelial cells (HUVEC), transfer experiment, micro-tube forming experiment, angiogenesis experiment of chick embryo allantois and mouse cornea experiment, and the decapetide can be used for preparing medicines for inhibiting angiogenesis.

The invention relates to the biological medicine, in particular to the application of chitosan oligosaccharide in preparing medicines used for treating tumors and restraining tumor metastasis, wherein, by taking a nutrient solution for tumor cells as an inducing factor and taking a human umbilical vein endothelial cell as an study object, the chitosan oligosaccharide can significantly restrain the human umbilical vein endothelial cell metastasis induced by the nutrient solution for tumor cells and the formation of tubular structure caused by the endothelial cell metastasis, but have no obvious restraining effect on the proliferation of the human umbilical vein endothelial cells metastasis induced by the nutrient solution for tumor cells.

The invention relates to the technical field of protein extraction, in particular to a method for preparing velvet antler active protein extracts. The method comprises the steps of conducting blood drawing, freeze-drying and smashing on fresh velvet antler to obtain velvet antler powder; mixing the velvet antler powder with a buffer solution, conducting ultrasonic extraction and centrifugation, collecting supernate, and conducting vacuum freeze drying to obtain the velvet antler protein extracts, wherein the pH value of the buffer solution is 7.0-8.0, and the concentration of the buffer solution is 10-50 mM. By the adoption of the method, the biological activity and extraction efficiency of velvet antler protein are maintained to the maximum degree. The velvet antler protein extracts prepared with the method can promote growth or proliferation of vascular cells, and particularly, the proliferation rate of human umbilical vein endothelial cells (HUVEC) reaches 200%.

The invention discloses a miichthys miiuy meat antioxidative peptide. The preparation method comprises the following steps: performing degreasing and complex enzyme enzymolysis by using micchthy miiuymeat as a raw material to obtain enzymatic hydrolysate; and performing ultrafiltration, macroporous resin desalination, anionic exchange resin chromatography, gel column chromatography and reversed high performance liquid chromatography separation and purification on the enzymatic hydrolysate to obtain antioxidative peptide Phe-Trp-Lys-Val-Val(FWKVV); and detecting the molecular weight which is 677.84 Da with ESI-MS. The high-activity antioxidative peptide Phe-Trp-Lys-Val-Val (FWKVV) has an excellent cleaning effect for DPPH free radical, hydroxyl radical and superoxide anion free radical, and has a protective effect for hydrogen peroxide induced human umbilical vein endothelial cell-HUVEC cell oxidative damage, has the advantages of safety, no toxicity or side effect, strong antioxicative activity and the like, and can be used as medicines, health foods or food additives and the like.

The present disclosure relates to compositions for and methods of improving wound healing, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The methods for wound healing administer one or more compositions including hydroxytyrosol and oleuropein with cells derived from umbilical cord blood.

The invention discloses an application of an LncRNA XLOC_057528 inhibitor to preparation of medicines for promoting blood vessel regeneration. Overexpression and silence of lncRNA XLOC_057528 confirmthat lncRNA XLOC_057528 can influence expression of a p53 gene and protein to human umbilical vein endothelial cells, and besides, confirm that the lncRNA XLOC_057528 participates in promotion of proliferation of the human umbilical vein endothelial cells, restraining of apoptosis of the human umbilical vein endothelial cells, and restraining of canaliculization of the human umbilical vein endothelial cells, and further confirm that the lncRNA XLOC_057528 can participate in restraining of blood vessel regeneration after miocardial infarction. Therefore, the lncRNA XLOC_057528 inhibitor can beused for preparing the medicines for promoting blood vessel regeneration, and particularly the lncRNA XLOC_057528 inhibitor can be used for preparing the medicines for promoting blood vessel regeneration after miocardial infarction.

A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.

The invention relates to application of genipin in prevention or treatment of ischemic brain injury. Brain injury is particularly related to injury of microglial cells or human umbilical vein endothelial cells. The invention further relates to a medicine composition containing genipin for preventing or treating ischemic brain injury.

The invention discloses a depolymerized holothurian glycosaminoglycan composition, as well as a preparation method and application of the depolymerized holothurian glycosaminoglycan composition. The depolymerized holothurian glycosaminoglycan composition is one or more of depolymerized holothurian glycosaminoglycan with the weight-average molecular weight between 2000Da and 12000Da, and the preparation method of the depolymerized holothurian glycosaminoglycan composition comprises extracting and purifying holothurian glycosaminoglycan, degrading the holothurian glycosaminoglycan and the like. Screened through a plurality of experiments, echinodermata holothurian is chosen as an object of study, and an extracting and purifying process of the holothurian glycosaminoglycan and a degrading process of the depolymerized holothurian glycosaminoglycan are chosen from a large quantity of experiments. The whole process is reasonable in design and strong in operability, and the industrial production is implemented. The anti-tumor study shows that the depolymerized holothurian glycosaminoglycan composition remarkably inhibits the generation of a lumen of a human umbilical vein endothelial cell in vitro, inhibits the transfer of melanin and a breast cancer in vivo, has an excellent anti-tumor effect, is expected to be developed into an efficient antitumor drug or healthcare product with low toxic or side effects, and has an important application prospect.

The invention provides a p66Shc recombinant adenovirus vector. Homologous recombination in vitro of a human p66Shc fragment and a pAdeno X-CMV vector is realized by use of the gene engineering technology, and then competent bacteria are used for transformation to screen out correct recombinant adenoviruses; next, the recombinant adenoviruses are linearized and then used for transfecting HEK293A cells, and therefore, the recombinant adenoviruses are packaged and amplified largely in the HEK293A cells. After Hela cells are infected with the p66Shc recombinant adenovirus vectors, the growth and proliferation of the cells can be obviously inhibited; if human umbilical vein endothelial cells (HUVEC) are in infected with the p66Shc recombinant adenovirus vectors, no obvious growth inhibition effect is caused. The p66Shc recombinant adenovirus vector is expected to achieve a special growth inhibition effect on tumor cells.

The invention relates to application of total triterpenes in preparing drugs inhibiting angiogenesis. The application has the advantages that novel application of the total triterpenes in extractive of Actinidia chinensis roots is provided. An experiment proves that the total triterpenes 1,2,3,4 have remarkable inhibiting effect on multiplication of human umbilical vein endothelial cells (HUVEC) and canaliculization of HUVEC, have anti-angiogenic activity, and can serve as angiogenesis inhibitors. By means of the application of the total triterpenes in preparing the drugs inhibiting the angiogenesis, the anti-angiogenesis effect of the total triterpenes in the extractive of Actinidia chinensis roots is firstly found out, and the total triterpenes can serve as the angiogenesis inhibitors to be applied to treat new blood vessel dependence and new vessel related diseases including tumors, arthritis, skin and eye diseases, atherosclerosis and the like.

The invention belongs to the field of preparing traditional Chinese medicines, and relates to application of panax notoginseng flos saponin, as an active part extracted from Chinese herbal notoginseng flos, in preparing a medicine for promoting angiogenesis. Experimental results show that the panax notoginseng flos saponin disclosed by the invention has a protective effect on VRI induced vascular injury in an early stage and has a recovery effect of promoting angiogenesis in a later vascular development process; the panax notoginseng flos saponin has a proliferation function on human umbilical vein endothelial cells; moreover, the panax notoginseng flos saponin is more significant in effects of promoting angiogenesis and protecting blood vessel compared with panax notoginseng (root) saponin. The panax notoginseng flos saponin disclosed by the invention can serve as a raw material to further prepare a pharmaceutical preparation for promoting angiogenesis, and the pharmaceutical preparation is used for preventing and treating such diseases related to angiogenesis deficiency as coronary heart disease, myocardial ischemia, insufficient construction of collateral circulation complementarity, slow trauma and fracture healing and thronboangitis obliterans.

The invention discloses a medicinal fatheadtree branchlet or bark alkaloid new compound with the function of promoting endothelial injury repair. The compound is prepared by a method including the steps: crushing medicinal fatheadtree branchlet or bark stems, adding water, performing soaking and extracting, collecting extraction liquid and performing vacuum concentration to obtain medicinal fatheadtree branchlet or bark extracts; extracting the extracts to obtain a dichloromethane portion and an ethyl acetate portion; feeding the ethyl acetate portion to a silica gel column; performing elution by taking dichloromethane-methanol with the volume ratio of 95:(5-10):90 as an elution solvent; combining similar portions by TLC (thin-layer chromatography) analysis; feeding a preparative liquid phase, taking methanol water as an eluent and performing liquid chromatography preparation to obtain the medicinal fatheadtree branchlet or bark new compound. Based on a cell repair related mechanism, under theoretical guidance, the proliferative activity of the medicinal fatheadtree branchlet or bark new compound is intensively studied, and experimental study indicates that the medicinal fatheadtree branchlet or bark new compound can obviously promote proliferation of HUVEC (human umbilical vein endothelial cell) cells and endothelial cell scratch repair and can be used for preparing a drug for controlling inflammatory endothelial injury.

The invention belongs to the field of Chinese medicine production and relates to application of tanshinol derivatives in Chinese herbal medicine salvia in preparation of a pharmaceutical composition for preventing cardiovascular-related diseases. According to the in-vitro oxidation stress model experiment research, the result shows that the tanshinol derivatives can be used for preventing the cardiovascular-related diseases by protecting endothelial cells of a circulatory system. More specifically, the tanshinol derivatives can be used for achieving the effect of protecting endothelial cells by restraining transcriptional level of the cardiovascular-related diseases, restraining protein expression level of the cardiovascular-related diseases, restraining the production of reactive oxygen species and restraining the corresponding signal transduction pathway and transcription factor. According to the experimental result, the tanshinol derivatives have an obvious inbibitional effect on apoptosis of HUVEC (Human Umbilical Vein Endothelial Cells) induced by H2O2 and have an obvious protection effect on cells damaged by oxidative stress, and can be used for further preparing a drug for preventing cardiovascular-related diseases.

The invention provides an exogenous hydrogen sulfide donor, and discloses a therapeutic action of an anethol trithione derivative used as the exogenous hydrogen sulfide donor on cardiovascular diseases. The exogenous hydrogen sulfide donor can release hydrogen sulfide, can promote the growth of an HUVEC (human umbilical vein endothelial cell) atherosclerosis cell model, has an antiatherosclerotic effect, and hopefully becomes a new target drug researched and developed by drugs with antiatherosclerotic effects.

The invention belongs to the technical field of medicine, and relates to a hexamethoxyflavanone-rhamnosyl-rhamnoside and application thereof. The hexamethoxyflavanone-rhamnosyl-rhamnoside is prepared by the following steps: carrying out solvent extraction and extraction separation on murraya jasminorage, carrying out silica gel column separation, carrying out further separation by semipreparative chromatography, concentrating, and carrying out freeze-drying to obtain the finished hexamethoxyflavanone-rhamnosyl-rhamnoside product. The antitumor activity evaluation detects that the hexamethoxyflavanone-rhamnosyl-rhamnoside has low cytotoxicity; the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on the adhesion of colon cancer cells HT-29 and Fn (fibronectin) and the adhesion of HUVECs (human umbilical vein endothelial cells); the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on migration capacity (scratch heating experiment) and invasion capacity of HT-29; and the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on mouse in-vivo B16-F10 lung transfer. Therefore, the hexamethoxyflavanone-rhamnosyl-rhamnoside has tumor transfer inhibition activity, can be used for preparing anticancer drugs, and has favorable development and application prospects.

The invention relates to a human hemangioma animal model constructed by the following method: a, taking human hemangioma stem cells and human umbilical vein endothelial cells for later use; b, resuspending 8*105-1*1010 hemangioma stem cells and 7*104-1*1010 human umbilical vein endothelial cells with 100mu l of EGM-2 (endothelial cell growth medium-2) culture fluid, then mixing uniformly in 100mul of Matrigel with the protein concentration of 18-22mg/mL; and c, inoculating the mixture of the human hemangioma stem cells and the umbilical vein endothelial cells subcutaneously by a syringe intoan animal with immunodeficiency. The invention also provides a constructing method and application of the human hemangioma animal model. The invention has the advantages that the formed hemangioma iscompletely composed of humanized cells, the hemangioma model has the pathological characteristics of human hemangioma, and the hemangioma model is very suitable for researching and developing medicaments or methods for treating human hemangioma based on the pathogenesis of human hemangioma.